Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11792905 | 0.86 | CYP1A1 (0.34) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL29609923 | 0.86 | CYP1A1 (0.34) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL3703014 | 0.75 | CYP1A2 (0.45) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL9105068 | 0.73 | CYP1A1 (0.34) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL29609339 | 0.73 | CYP1A1 (0.34) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL11324753 | 0.72 | CYP1A2 (0.42) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL9101264 | 0.68 | CYP1A2 (0.43) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL1043402 | 0.66 | CYP2B6 (0.43) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL29365059 | 0.66 | CYP2B6 (0.43) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL29372595 | 0.66 | CYP2B6 (0.43) | CYP1A1CYP1A2CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
| WO-2012040641-A2 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | CYP1A1 3366/4885CYP1A2 3484/4885CYP2B6 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.